2022 in Review: Best in MBC with Dr. Erika Hamilton
Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.
LBBC - Silent Voices No Longer
This season, we are bringing back our Trailblazer series. Our first trailblazer is Living Beyond Breast Cancer (LBBC), a national non-profit that has become synonymous with the word community. That’s because LBBC’s annual Conference on MBC is one of the largest gatherings for women and men living with MBC. In this episode we will speak with Jean Sachs, CEO of LBBC, and sprinkled throughout this episode are your voices, voices of patients sharing their LBBC experience.
Meditation, Mindfulness, and MBC: Finding Your Inner Calm
Can mindfulness and meditation help many of us living with MBC tame anxiety, improve emotional balance, and experience more joy? Expert guests and our patient panel share how this ancient practice can make a daily difference. Bonus: our podcast includes a special guided meditation created with MBC patients in mind.
Laughter as Medicine
Is laughter good medicine? These breast cancer survivors/thrivers say: Yes!
Systemic Racism and MBC in Clinical Trials
Jumping hurdles to get the treatments you want is the reality for people living with MBC. Add systemic racism into the healthcare mix and it’s clear that more needs to happen, and soon, to create equity and greater diversity in one of the most important tools in the MBC toolbox: clinical trials. In this episode, we check in with Stephanie Walker, who led the BECOME project and spearheads the Black Wo(Men) Speak Symposium, patient advocate and clinical trial participant Rev. Dr. Tawana Davis, and Patient Navigator Valarie Worthy. How does systemic racism affect what Black patients learn about MBC clinical trials? And how can those who need it most break down barriers to the best care?
ASCO 2022: When The Dust Settles, What Are My Treatment Options For ER+/HER2- MBC?
Welcome to the second part of our post–2022-ASCO analysis of the state of affairs in the HR-positive MBC. It was not so long ago that our only options were single-agent endocrine therapy and systemic chemo. We have come a long way over the last couple of decades. Today we are asking Drs. Stephanie Graff, Sara Hurvitz, and Kevin Kalinsky to talk about how they make decisions in the clinic in selecting and sequencing treatments, specifically CDK4/6 inhibitors and the newly approved targeted therapies.
RTAC: FES/Cerianna Screening for Estrogen Positive MBC
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
Caregivers: We Can’t Do This Without You!
Celebrate OMBCL’s 100th episode and National Family Caregiver Month by listening to our candid conversations with three committed and courageous caregivers.
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?
While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.
We Remember
We Remember honors all who died from metastatic breast cancer over the past year—parents, children, spouses and partners. In this episode, the MBC community gives voice to both the grief and the love that endures after each death.
Dr. Shanu Modi: How to Get a Standing Ovation at ASCO?
MSK’s Dr. Shanu Modi, lead investigator on the DESTINY-Breast04 trial, talks with the Our MBC Life team about the trial’s standing ovation at ASCO, how to know if we’re HER2-low, and what this all means for us.
MBC101: The HER2-Low Show
The DESTINY-Breast04 trial at ASCO 2022 introduced many people to the term “HER2-low.” But how do you know if you’re HER2-low? In this episode, with the help a breast pathologist and a clinical oncologist we dive into this subtype and what it means to us.
The Legacy of Lisa Laudico
Lisa Laudico, who created and spearheaded the Our MBC Life podcast series, died on August 6, 2022 from MBC. In this episode, Lisa’s friends, family, and colleagues remember her amazing life and celebrate the many ways she fostered connection, resilience, and hope throughout the MBC community.
Season 5: Interviews, MBC101, Giveaways, and Much More…
The Our MBC Life senior producers and co-hosts, Victoria Goldberg and Natalia Green join Anne Woodward in a conversation about the upcoming season 5 of the podcast and some new things the team is doing and exciting details for very special giveaways for the Our MBC Life merchandise.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Psilocybin-assisted Therapy: One Patient vs. the DEA
Welcome to the third and final episode in our series on the potential of psilocybin-assisted therapy to relieve the existential distress of, and help us live as well as possible with, metastatic breast cancer.
In this episode, we speak with two women taking action to increase legal access to psilocybin-assisted therapy in the United States. The first is a patient living with MBC who, along with her doctor, have brought a lawsuit against the Drug Enforcement Agency which is denying her access to psilocybin in the palliative care setting and under existing Right to Try laws for promising investigational medications for the terminally ill. The patient petitioner, Erinn Baldeschwiler, tells us why she joined the lawsuit, what she hopes to gain from psilocybin-assisted therapy, and what it’s been like to deal with all the legal proceedings on top of a progressing MBC diagnosis.
Our second interview in this episode is with the attorney who is leading the legal case to open access to psilocybin under Right to Try legislation, Kathryn Tucker of the Emerge Law Group. Kathryn explains why psilocybin should be immediately available to patients suffering from distress, anxiety, depression under FDA rules and state and federal Right to Try laws. But the DEA is continuing to block access and hold psilocybin on Schedule 1 of the Controlled Substance Act.
It’s confusing, but we explain it all here. Lastly, see the Episode Notes for a current petition to the DEA to step out of the way and grant access to psilocybin for anyone with a terminal illness.
This series has been led by series producer, Dr. Paula Jayne with assistance from co-host Lynda Weatherby, and senior producer and host Lisa Laudico.
Thanks for listening!
Psilocybin-assisted Therapy: Patient Experiences
Welcome to the second episode in our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this episode, we talk to two women with breast cancer who had legal access to psilocybin-assisted therapy. Journalist and writer Erica Rex participated in a clinical trial at Johns Hopkins after being diagnosed with early-stage breast cancer. Maari Singfield, a young Canadian woman living with MBC, gained access through an exemption to Section 56(1) of the Canadian Controlled Drugs and Substances Act, a process facilitated by the organization, TheraPsil.
Both women shared with us the process that they went through to gain legal access to psilocybin-assisted therapy, what the treatment was actually like for them, and what, if anything, changed in their lives afterward.
Healing our Distress: The Potential of Psilocybin-assisted Therapy
Welcome to our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this first episode, co-host and producer of this series, Dr. Paula Jayne and co-host Lynda Weatherby interview Dr. Boadie Dunlop, Director of the Mood and Anxiety Disorders Program at Emory University. Dr Dunlop shares existing and emerging data on how psilocybin may help those of us living with MBC and discusses an upcoming pilot trial of psilocybin-assisted therapy at Emory University’s Palliative and Supportive Care Clinic.
MBC & Parenting Expert Panel
How does one even begin to bring up the topic of metastatic breast cancer to a child? On this third episode of our MBC & Parenting series, we’ll talk to three experts that can give us some insight and guidance on how to talk with our children in the most open and safe ways. First up, Co-host Martha Carlson and Senior Co-host Victoria Goldberg speak with Dr. Leeza Park, psychiatrist, clinical researcher, and Deputy Director for the Comprehensive Cancer Support Program at the University of North Carolina (UNC) at Chapel Hill. Finally, Senior Co-host and Producer, Lisa Laudico and Co-host Martha Carlson have an illuminating conversation with Morgan Livingstone, Certified Child Life Specialist based in Toronto, Ontario Canada, and Amanda Celeste, Parenting Expert for Project Life, mother, wife, and teacher.
MBC & Parenting: The Kids Are Alright
What does a metastatic diagnosis mean for our children?